Transcarent CEO Glen Tullman spent much of 2024 hinting that his health benefits upstart might be shopping around for acquisitions, and just over a week into the new year, he’s making good on it: Transcarent on Wednesday announced it will buy Accolade, another benefits company, for $621 million — more than double Accolade’s value on the stock market the day before.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
